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A case of syringotropic mycosis fungoides without internal organ involvement received total skin elec-
tron beam therapy (TSEBT) and evolved into poikilodermatous mycosis fungoides. Subsequent oral
psoralen plus ultraviolet A (PUVA) therapy achieved complete remission. The value of TSEBT for syrin-
gotroopic mycosis fungoides is illustrated in this case.
Copyright  2013, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. All rights reserved.Introduction left chest wall and left lower back (Figure 1A). No alopecia on theSyringotropic mycosis fungoides (MF) is a rare variant character-
ized by prominent involvement of the eccrine glands with syrin-
gometaplastic lymphoepithelial lesions.1 It is currently classiﬁed in
adnexotropic MF, which also includes folliculotropic MF.2 Typically,
MF manifests as patches, plaques, and tumors.3 According to the
largest case review of syringotropic MF to date,1 the individual le-
sions were mainly punctate erythematous papules, plaques, and
nodules. Seventy percent of patients had concomitant follicular
involvement andmay have shown alopecia or anhidrosis. Given the
rarity of the disease, no consensus of treatment has been published.
Generalized syringotropic MF has been reported to be responsive to
extracorporeal photophoresis,4 which is not available at our insti-
tution so far. We report a case of generalized syringotropic MF
responsive to the total skin electron beam therapy (TSEBT) and
presenting a transition to poikilodermatous MF.
Case report
A 31-year-old man presented with a 5-year history of generalized
erythematous papules and plaques. Some red papules were in the
corresponding follicular area. Painful ulcers were also noted on they have no ﬁnancial or non-
tter or materials discussed in
Chang Gung Memorial Hos-
).
iwanese Dermatological Associatioskin was observed. The patient reported decreased sweat produc-
tion on the affected chest wall. The skin lesions were unresponsive
to topical corticosteroids. A skin biopsy taken from his left chest
wall showed focal epidermal necrosis, diffuse heavy inﬁltrates of
small- to medium-sized atypical lymphoid cells throughout the
dermis with little epidermotropism (Figure 1B). These atypical
lymphoid cells were found in syringometaplastic lymphoepithelial
lesions (Figure 1C). Immunohistochemical study showed that the
lymphoid cells were mainly CD2þ, CD3þ, and CD8þ T cells. The
clonal proliferation of T cells was conﬁrmed by a T-cell receptor
(TCR) gene rearrangement analysis using the BIOMED-2 multiplex
polymerase chain reaction assay with both heteroduplex and
GeneScan analyses (Figure 2).5 After the complete staging work-up
for lymphoma, including whole body computed tomography scan
and bone marrow biopsy, the patient was diagnosed to have
syringotropic MF stage IB (T2N0M0).
Subsequently, the patient received TSEBT modiﬁed from the
Stanford protocol for 3600 cGy in 36 fractions.6 According to the
results of in vivo dose measurement with a thermo-illuminescent
dosimeter, several localized regions of extreme dose nonunifor-
mity (underdose) on the patient’s surface received additionally
local electron boost during the course of TSEBT. These underdose
regions included soles (electron boost with 2210 cGy in 13 frac-
tions) and perineum (1800 cGy in 13 fractions). Moreover, a
simultaneous electron boost to the lesions with deep inﬁltration
during the course of TSEBT was also delivered at the left chest wall
and the left ﬂank (additionally 1300 cGy in 15 fractions).
After the TSEBT, hyperpigmented patches, telangiectasia on
mildly hypopigmented atrophic and scarring skin developed on then. Published by Elsevier Taiwan LLC. All rights reserved.
Figure 1 Clinical picture of the patient before total skin electron beam therapy. (A) Multiple erythematous plaques on the trunk and upper extremities. Note ulcers on the left upper
chest lesion. (B) Heavy lymphoid cell inﬁltrates are seen in the upper dermis and scattered aggregates in the lower part (hematoxylin and eosin stain, 20). (C) Islands of lym-
phoepithelial lesions are inﬁltrated by lymphoid cells indicating syringotropic mycosis fungoides (hematoxylin and eosin stain, 200).
Figure 2 T-cell receptor gene rearrangement study of the original syringotropic mycosis fungoides lesion showing clonal Vb-Jb1, Db-Jb, and Vgf1-Jg rearrangements in GeneScan
analysis.
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Figure 3 (A) The skin lesions after total skin electron beam treatment. The plaques became ﬂattened with poikilodermatous change. (B) Lymphoid cell inﬁltrates are present only in
the superﬁcial dermis (hematoxylin and eosin stain, 20). (C) Higher magniﬁcation shows epidermotropic lymphoid cells and vacuolar degeneration of basal cells with melanin
incontinence consistent with poikilodermatous mycosis fungoides (hematoxylin and eosin stain, 200).
P.-H. Lu et al. / Dermatologica Sinica 32 (2014) 172e175174previously involved area (Figure 3A). A skin biopsy from the left
chest wall showed diffuse heavy inﬁltrates of small to medium
sized lymphoid cells in papillary dermis (Figure 3B) with vacuolar
degeneration of the basal layer, melanin incontinence and atrophic
epidermis (Figure 3C). No syringotropic inﬁltration was seen. TheFigure 4 T-cell receptor gene rearrangement study on skin biopsy tissue of poikilodermato
patterns as seen in the initial study shown in Figure 2.lymphoid cells were mainly positive for CD3 and CD4. Repeated
TCR gene rearrangement study showed identical patterns for
clonality status in the skin biopsy tissue from skin lesions after
TSEBT (Figure 4). The patient’s diagnosis was changed from syrin-
gotropic MF to poikilodermatous MF. Since the involvement ofus mycosis fungoides after total skin electron beam therapy detected identical clonal
P.-H. Lu et al. / Dermatologica Sinica 32 (2014) 172e175 175lymphoma inﬁltration was conﬁned within the papillary dermis,
we shifted the therapy to oral psoralen plus ultraviolet-A (PUVA)
treatment. Local radiotherapy was delivered to the lesions of re-
sidual disease with unsatisfactory response. The patient had
generalized hyperpigmentation after PUVA treatment. His ulcers
healed, and he maintained the PUVA treatment three times a week
for 6 months. The follow-up biopsy showed no lymphoma cells in
the skin ﬁnally. The patient achieved complete remission status,
and maintenance PUVA treatment was given once a week. He has
since been alive without disease for 6 months.
Discussion
Our case was unique in the presentation of painful shallow ulcers in
addition to the punctate follicular corresponding papules. The ul-
ceration in syringotropic MF may stand for more advanced disease.
In addition, the poikilodermatous lesions developed after TSEBT.
Poikilodermatous MF is another variant of MF with hypo-
pigmentation, hyperpigmentation, skin atrophy, and telangiectasia
in addition to the red patches and plaques seen in conventional
MF.7 After the TSEBT, the atrophy of the skin and aggravated ul-
ceration could be attributed to the side effects from the treatment
per se.8 However, the radiation would not cause the vacuolar
degeneration of the basal layer. The true mechanism of the tran-
sition from syringotropic MF to poikilodermatous MF remains un-
known. Our case also showed the shift from CD8þMF to CD4þMF,
which has been observed in other case of T-cell lymphoma and the
pathogenesis is unclear.9
The diagnosis of syringotropic MF and poikilodermatous MF in
our case were supported by the clonal T-cell proliferation. The use
of the TCR gene rearrangement study aids in the conﬁrmation of
lymphoma cells. The clonality detection rate by BIOMED-2 TCR
multiplex polymerase chain reaction protocol is 99% for T-cell
malignancy.5 However, clonality per se does not necessarily equal
malignancy, careful clinicopathologic correlation is mandatory for
making an accurate diagnosis.
Because of involvement of deeper structures in syringotropic
MF, topical therapies are often unsuccessful.4 Only two cases of
syringotropicMF have reported complete remission.1,4 The ﬁrst was
the solitary syringotropic MF, but the treatment modality givenwas
not mentioned.1 The second was the generalized syringotropic MF
responsive to extracorporeal photophoresis and maintenance use
of oral bexarotene.4 In other cases of syringotropic MF, patients had
variable response to PUVA treatment,10 narrow-band ultraviolet-B
phototherapy, and topical treatments with bexarotene gel and
clobetasol ointment.11 In our case, TSEBT is a good treatment mo-
dality for generalized syringotropic MF without the evidence of
internal organ involvement. Whole-skin irradiation treatment can
be delivered to a mean depth of 3 mmwith a 6 MeV electron beam
produced by a linear accelerator and accumulated to a total dose of
24 Gy in 8 fractions divided into 3 times a week.12 Because the
eccrine glands are located at the junction between the reticular
dermis and subcutaneous layer, regular PUVA treatment cannot
reach the level of eccrine glands. Our case showed good response to
TSEBT, which should be considered as one of the ﬁrst-line treat-
ments in cases of generalized syringotropic MF without anyinternal organ involvement. After our case showed only superﬁcial
involvement of MF in the epidermis and papillary dermis, we used
the PUVA treatment since there was limitation of the highest dose
of electron beam and PUVA can only reach less than 160 um deep in
the skin.13
One review of 20 cases of syringotropic cutaneous T-cell lym-
phoma indicated that the disease had a prognosis similar to chronic
forms of conventional MF, with 10-year survival ranging from 83%
to 97% depending on the extent of cutaneous involvement.14 We
had followed our case for 3 years after the initial diagnosis of
syringotropic MF and he was still alive without disease for 6
months. As in the treatment for conventional MF, continuous
follow-up with maintenance treatment are considered mandatory
in treating syringotropic MF.
Syringotropic MF is a rare variant of MF warranting further
clinical and pathologic identiﬁcation by the dermatologists and
dermatopathologists. The transition from syringotropic MF to poi-
kilodermatousMFmight be associated with the effect of TSEBT. The
pathophysiology and prognosis of syringotropic MF require further
studies. Different treatment modalities should be considered when
treating various types of MF.References
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